KRON
Kronos Bio Inc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website kronosbio.com
- Employees(FY) 99
- ISIN US50107A1043
Performance
-2.86%
1W
-6.42%
1M
0.0%
3M
-3.77%
6M
-18.4%
YTD
-43.96%
1Y
Profile
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Technical Analysis of KRON 2024-05-10
Overview:
In analyzing the technical indicators for KRON over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-15 21:35
- 2024-05-09 10:55
- 2024-05-09 05:45
- 2024-05-09 04:05
Kronos Bio Reports First-Quarter 2024 Financial Results(Globenewswire)
- 2024-04-24 04:01
- 2024-03-27 00:00
- 2024-03-21 01:53
- 2024-03-20 19:05
- 2024-03-07 03:05
- 2024-03-05 03:44
- 2024-02-27 03:05
- 2024-01-24 19:00
- 2023-12-18 03:06
- 2023-12-03 19:00
- 2023-11-27 03:05
- 2023-11-13 04:25
- 2023-11-13 03:05
- 2023-11-02 04:05
- 2023-11-02 00:00
- 2023-10-26 20:00
- 2023-10-13 00:30
- 2023-10-04 04:05
- 2023-08-16 20:00
- 2023-08-08 05:50
- 2023-08-08 04:05
- 2023-07-18 19:27
- 2023-06-05 20:00
- 2023-06-01 04:05
- 2023-05-11 19:00
- 2023-05-10 05:35
Page 1 of 4
previousnext